{"id":587498,"date":"2022-02-21T18:26:01","date_gmt":"2022-02-21T18:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=587498"},"modified":"2022-02-21T18:26:01","modified_gmt":"2022-02-21T18:26:01","slug":"systemic-mastocytosis-pipeline-review-analysis-into-the-novel-and-emerging-therapies-clinical-trials-and-treatment-outlook-key-companies-allakos-novartis-deciphera-azur-pharma-and-cstone","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/systemic-mastocytosis-pipeline-review-analysis-into-the-novel-and-emerging-therapies-clinical-trials-and-treatment-outlook-key-companies-allakos-novartis-deciphera-azur-pharma-and-cstone_587498.html","title":{"rendered":"Systemic Mastocytosis Pipeline Review: Analysis into the Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Key Companies &#8211; Allakos, Novartis, Deciphera, Azur Pharma, and CSTONE"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Systemic Mastocytosis Pipeline Review: Analysis into the Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Key Companies - Allakos, Novartis, Deciphera, Azur Pharma, and CSTONE\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Systemic Mastocytosis Pipeline Review: Analysis into the Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Key Companies - Allakos, Novartis, Deciphera, Azur Pharma, and CSTONE\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cSystemic Mastocytosis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Systemic Mastocytosis Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Systemic Mastocytosis Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Systemic Mastocytosis Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/bd064f4b01c71dc1095f06b74136327f.jpg\" alt=\"Systemic Mastocytosis Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Systemic Mastocytosis Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Systemic Mastocytosis<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>Systemic Mastocytosis Treatment<\/strong>.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Systemic Mastocytosis key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Systemic Mastocytosis Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Systemic Mastocytosis market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/systemic-mastocytosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Systemic Mastocytosis Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Companies worldwide are performing studies to develop a safe and effective treatment option for the patients suffering from Systemic Mastocytosis<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Systemic Mastocytosis Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Allakos<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Deciphera<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Azur Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CSTONE Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Systemic Mastocytosis Therapies covered in the report include:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gleevec (Imatinib)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rydapt (Midostaurin)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gastrocrom<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Avapritinib (CS3007)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ripretinib (DCC-2618)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AK002<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/systemic-mastocytosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Systemic Mastocytosis&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Systemic Mastocytosis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Systemic Mastocytosis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Systemic Mastocytosis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Systemic Mastocytosis Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Systemic Mastocytosis Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Systemic Mastocytosis Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Systemic Mastocytosis Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Systemic Mastocytosis Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Systemic Mastocytosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Systemic Mastocytosis Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Systemic Mastocytosis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-mastocytosis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/systemic-mastocytosis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Healthcare Report by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/malignant-pleural-mesothelioma-market\">Malignant Pleural Mesothelioma (MPM) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Malignant Pleural Mesothelioma (MPM) Market is anticipated to grow in the coming years owing to the improvement in healthcare spending across the world, rising prevalence, and the active participation of the key companies in therapeutics domain such as Sellas, Polaris Pharma, Targovax, among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=systemic-mastocytosis-pipeline-review-analysis-into-the-novel-and-emerging-therapies-clinical-trials-and-treatment-outlook-key-companies-allakos-novartis-deciphera-azur-pharma-and-cstone\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=systemic-mastocytosis-pipeline-review-analysis-into-the-novel-and-emerging-therapies-clinical-trials-and-treatment-outlook-key-companies-allakos-novartis-deciphera-azur-pharma-and-cstone\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cSystemic Mastocytosis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Systemic Mastocytosis Market. The Systemic Mastocytosis Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/systemic-mastocytosis-pipeline-review-analysis-into-the-novel-and-emerging-therapies-clinical-trials-and-treatment-outlook-key-companies-allakos-novartis-deciphera-azur-pharma-and-cstone_587498.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-587498","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/587498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=587498"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/587498\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=587498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=587498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=587498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}